logo
Is Roku (ROKU) a Good Stock to Buy before Earnings?

Is Roku (ROKU) a Good Stock to Buy before Earnings?

Shares of Roku (ROKU) closed lower in today's trading as investors await its Q1 earnings results on May 1 after the market closes. Analysts are expecting earnings per share to come in at -$0.26 on revenue of $1.01 billion. According to TipRanks' data, this equates to 25.7% and 14.6% year-over-year increases, respectively.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Interestingly, analysts at Citizens JMP seem to be optimistic about Roku's performance going forward. Indeed, the investment firm recently reiterated its Outperform rating and $95 price target on Roku after attending the company's Roku Experience event in New York City. In a note to investors, the firm said it came away from the event even more confident in Roku's unique operating system and its ability to boost platform monetization. The analysts added that they believe Roku is well-positioned to keep improving how it generates revenue from its platform.
Separately, it is also worth noting that Roku's active accounts have been steadily increasing over the past five years, according to Main Street Data. At the same time, the average revenue per user has stabilized at around $40 over the past few years.
What Do Options Traders Anticipate?
Using TipRanks' Options tool, we can see that options traders are expecting a 13.9% move from ROKU stock in either direction right after its earnings report. The expected earnings move is determined by calculating the at-the-money straddle of the options closest to expiration after the earnings announcement.
It's worth noting that ROKU's after-earnings price moves in the past 12 quarters have mostly been larger than the 13.4% that is expected. This implies that current option prices might have a decent chance of being profitable and are potentially undervalued.
What Is the Fair Value of Roku Stock?
Overall, analysts have a Moderate Buy consensus rating on ROKU stock based on 14 Buys, nine Holds, and one Sell assigned in the past three months, as indicated by the graphic below. Furthermore, the average ROKU price target of $94.19 per share implies 38.2% upside potential.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Oppenheimer Remains a Buy on Nurix Therapeutics (NRIX)
Oppenheimer Remains a Buy on Nurix Therapeutics (NRIX)

Business Insider

time2 hours ago

  • Business Insider

Oppenheimer Remains a Buy on Nurix Therapeutics (NRIX)

Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) yesterday and set a price target of $32.00. The company's shares closed last Friday at $11.93. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Biegler is an analyst with an average return of -12.1% and a 31.68% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Regeneron, and Nurix Therapeutics. In addition to Oppenheimer, Nurix Therapeutics also received a Buy from Truist Financial's Srikripa Devarakonda in a report issued on June 13. However, on June 3, Leerink Partners reiterated a Hold rating on Nurix Therapeutics (NASDAQ: NRIX).

Honeywell open to acquiring more companies in Europe, Bloomberg says
Honeywell open to acquiring more companies in Europe, Bloomberg says

Business Insider

time4 hours ago

  • Business Insider

Honeywell open to acquiring more companies in Europe, Bloomberg says

Honeywell (HON) is open to acquiring more companies in Europe as it looks to increase its portfolio, Kate Duffy of Bloomberg reports. 'We're open across the board where those things fit,' Chief Commercial and Strategy Officer Ben Driggs said in an interview, according to Bloomberg. 'There is absolutely growth in defense that we want to take advantage of.' Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Ord Minnett Remains a Buy on Regis Healthcare Ltd. (REG)
Ord Minnett Remains a Buy on Regis Healthcare Ltd. (REG)

Business Insider

time4 hours ago

  • Business Insider

Ord Minnett Remains a Buy on Regis Healthcare Ltd. (REG)

Ord Minnett analyst Tom Godfrey maintained a Buy rating on Regis Healthcare Ltd. (REG – Research Report) today and set a price target of A$8.25. The company's shares opened today at A$7.36. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Godfrey is a 3-star analyst with an average return of 7.9% and a 36.73% success rate. Godfrey covers the Healthcare sector, focusing on stocks such as Monash IVF Group Ltd, Sigma Healthcare Ltd, and EBOS Group Limited. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Regis Healthcare Ltd. with a A$8.93 average price target, representing a 21.33% upside. In a report released on June 5, Jefferies also maintained a Buy rating on the stock with a A$8.80 price target.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store